APA (7th ed.) Citation

Lopes, R. D., Alings, M., Connolly, S. J., Beresh, H., Granger, C. B., Mazuecos, J. B., . . . Healey, J. S. (2017). Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. The American heart journal, 189, 137-145. https://doi.org/10.1016/j.ahj.2017.04.008

Chicago Style (17th ed.) Citation

Lopes, Renato D., et al. "Rationale and Design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) Trial." The American Heart Journal 189 (2017): 137-145. https://doi.org/10.1016/j.ahj.2017.04.008.

MLA (9th ed.) Citation

Lopes, Renato D., et al. "Rationale and Design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) Trial." The American Heart Journal, vol. 189, 2017, pp. 137-145, https://doi.org/10.1016/j.ahj.2017.04.008.